Long-Term Follow-Up of Subjects Treated With NTLA-2002

• Research type

  Research Study

• Full title

  Long-Term Follow-Up of Subjects Treated With NTLA-2002

• IRAS ID

  1008843

• Contact name

  Peggy Sung

• Contact email

  peggy.sung@intelliatx.com

• Sponsor organisation

  Intellia Therapeutics, Inc.

• Eudract number

  2022-003778-22

• Research summary

  This Study aims to Evaluate the long term effects of NTLA-2002 in adults with Hereditary Angioedema (HAE). The purposes of this study are to evaluate the long-term safety of NTLA-2002 in previously treated subjects and evaluate the long-term efficacy of NTLA-2002 in previously treated subjects.
  When subjects complete or prematurely discontinue a previous Intellia study with NTLA-2002, they will be asked to consent and participate in this long-term follow-up study, in order to better define the benefit-risk profile of treatment with NTLA-2002. No investigational drugs will be administered during this study.

• REC name

  London - West London & GTAC Research Ethics Committee

• REC reference

  23/LO/0904

• Date of REC Opinion

  4 Jan 2024

• REC opinion

  Further Information Favourable Opinion